Novartis in Society Integrated Report 2023
Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.
Novartis 2023 Financial Results
Novartis announces the company’s fourth quarter and 2023 full year financial results.
Discover our medicines
Our innovative medicines address society’s greatest disease burdens and restore possibility for patients.
Explore our science
Discover how we unravel the mysteries of biology and develop new technologies to fight disease and change lives.
Learn about our impact
Creating a medicine is just the beginning of the journey. Discover how we embrace societal impact as a core business objective.
Novartis Appoints Sloan Simpson as Global Head of Investor Relations
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
Our next era
Meet the new Novartis as we begin our next phase as an innovative medicines company.